Related Experiment Video
Updated: Jun 21, 2026
06:26
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Biotech acquisitions by big pharma: why and what is next
1Institute of Biotechnology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QT, UK. nafees_malik@hotmail.com
Drug Discovery Today
|July 9, 2009
Summary
Pharmaceutical companies are acquiring biotech firms to boost their drug pipelines. This analysis explores ideal acquisition targets and the financial crisis
Area of Science:
- Biotechnology
- Pharmaceutical industry
- Mergers and acquisitions
Background:
- Leading pharmaceutical companies are increasingly engaging in biotech acquisitions.
- These acquisitions aim to replenish and strengthen the drug development pipelines of major pharmaceutical firms.
- The current financial crisis presents unique challenges and considerations for these strategic deals.
Purpose of the Study:
- To identify the key characteristics that define a desirable biotech acquisition target for pharmaceutical companies.
- To analyze the potential impact of the ongoing financial crisis on the valuation and execution of biotech acquisition deals.
- To provide insights into the strategic decision-making process for pharmaceutical companies pursuing biotech M&A.
Main Methods:
- Qualitative analysis of recent pharmaceutical-biotech acquisition trends.
- Review of financial market indicators and economic forecasts relevant to the pharmaceutical sector.
- Case study approach examining specific acquisition targets and deal structures.
Main Results:
- Key target characteristics include strong intellectual property, promising clinical trial data, and innovative technology platforms.
- The financial crisis may lead to more cautious deal-making, potentially lower valuations, and increased scrutiny of target company financials.
- Certain biotech sub-sectors may be more resilient or attractive despite economic downturns.
Conclusions:
- Strategic biotech acquisitions remain crucial for pharmaceutical innovation and pipeline sustainability.
- Navigating the current financial climate requires a rigorous assessment of target value and a flexible negotiation approach.
- Understanding market dynamics is essential for successful pharmaceutical-biotech deal-making in uncertain economic times.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
03:00Next-generation Sequencing
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
02:55Synthetic Biology
Synthetic biology is an interdisciplinary science that involves using principles from disciplines such as engineering, molecular biology, cell biology, and systems biology. It involves remodeling existing organisms from nature or constructing completely new synthetic organisms for applications such as protein or enzyme production, bioremediation, value-added macromolecule production, and the addition of desirable traits to crops, to name a few.
Golden rice
Golden rice is a genetically modified...
Golden rice
Golden rice is a genetically modified...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...